MIRM Mirum Pharmaceuticals Inc
Price (delayed)
$44.56
Market cap
$2.18B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.85
Enterprise value
$2.28B
Mirum Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. Mirum's lead product candidate, maralixibat,
Highlights
The company's gross profit has surged by 83% YoY and by 14% QoQ
The revenue has soared by 81% YoY and by 10% from the previous quarter
The quick ratio has declined by 30% year-on-year and by 7% since the previous quarter
Mirum Pharmaceuticals's equity has decreased by 9% YoY and by 2.8% from the previous quarter
Key stats
What are the main financial stats of MIRM
Market
Valuations
Earnings
Shares outstanding
49.01M
Market cap
$2.18B
Enterprise value
$2.28B
Price to earnings (P/E)
N/A
Price to book (P/B)
9.48
Price to sales (P/S)
6.29
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
6.76
Revenue
$336.89M
Gross profit
$255.25M
Operating income
-$87.61M
Net income
-$87.94M
EBIT
-$72.6M
EBITDA
-$47.62M
Free cash flow
$9.33M
Per share
Balance sheet
Liquidity
EPS
-$1.85
EPS diluted
-$1.85
Free cash flow per share
$0.2
Book value per share
$4.7
Revenue per share
$7.09
TBVPS
$8.86
Total assets
$670.75M
Total liabilities
$445.11M
Debt
$317.76M
Equity
$225.64M
Working capital
$266.24M
Debt to equity
1.41
Current ratio
3.1
Quick ratio
2.84
Net debt/EBITDA
-1.99
Margins
Efficiency
Dividend
EBITDA margin
-14.1%
Gross margin
75.8%
Net margin
-26.1%
Operating margin
-26%
Return on assets
-13.3%
Return on equity
-38.2%
Return on invested capital
-20.1%
Return on capital employed
-13.3%
Return on sales
-21.6%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
MIRM stock price
How has the Mirum Pharmaceuticals stock price performed over time
Intraday
-1.04%
1 week
2.63%
1 month
-12.11%
1 year
60.46%
YTD
7.76%
QTD
7.76%
Financial performance
How have Mirum Pharmaceuticals's revenue and profit performed over time
Revenue
$336.89M
Gross profit
$255.25M
Operating income
-$87.61M
Net income
-$87.94M
Gross margin
75.8%
Net margin
-26.1%
The company's gross profit has surged by 83% YoY and by 14% QoQ
The revenue has soared by 81% YoY and by 10% from the previous quarter
The company's net margin has surged by 70% YoY and by 20% QoQ
The operating margin has soared by 56% YoY and by 17% from the previous quarter
Growth
What is Mirum Pharmaceuticals's growth rate over time
Valuation
What is Mirum Pharmaceuticals stock price valuation
P/E
N/A
P/B
9.48
P/S
6.29
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
6.76
The EPS has soared by 54% YoY and by 11% from the previous quarter
MIRM's price to book (P/B) is 63% higher than its 5-year quarterly average of 5.8 and 32% higher than its last 4 quarters average of 7.2
Mirum Pharmaceuticals's equity has decreased by 9% YoY and by 2.8% from the previous quarter
The revenue has soared by 81% YoY and by 10% from the previous quarter
MIRM's price to sales (P/S) is 8% higher than its last 4 quarters average of 5.8
Efficiency
How efficient is Mirum Pharmaceuticals business performance
The ROS has soared by 73% YoY and by 21% from the previous quarter
The ROIC has soared by 59% YoY and by 17% from the previous quarter
Mirum Pharmaceuticals's return on assets has surged by 58% YoY and by 13% QoQ
The ROE has soared by 57% YoY and by 10% QoQ
Dividends
What is MIRM's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for MIRM.
Financial health
How did Mirum Pharmaceuticals financials performed over time
MIRM's total assets is 51% higher than its total liabilities
The company's current ratio fell by 30% YoY and by 7% QoQ
The quick ratio has declined by 30% year-on-year and by 7% since the previous quarter
The company's debt is 41% higher than its equity
The debt to equity has grown by 14% YoY and by 2.9% from the previous quarter
Mirum Pharmaceuticals's equity has decreased by 9% YoY and by 2.8% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.